Top Abstract Purchase Related
Home
>
Node
>
Subnode

Experimental parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Kryzhanovskiĭ, G.N.; Atadzhanov, M.A.; Zagorevskiĭ, V.A.; Sharkova, L.M.; Voronina, T.A.

Biulleten' Eksperimental'noi Biologii i Meditsiny 105(4): 397-401

1988

ISSN/ISBN: 0365-9615
PMID: 3258764
Document Number: 321608
Systemic administration of high doses of MPTP caused transient bradykinesia, "freezing" episodes, head tremors, hunching of the back and peripheral autonomic effects. Neurological syndrome was clearly dose-dependent. It has been established that Parkinson's syndrome is caused by high-amplitude paroxysmal discharges in the nucleus caudatis. It is concluded that the nucleus caudatis plays the role of a pathological determinant structure in the development of Parkinson's syndrome induced by MPTP.

Document emailed within 1 workday
Secure & encrypted payments

Gugutsidze, D.A.; Nerobkova, L.N.; Boronina, T.A. 1989: Analysis of sleep-wakefulness structure in parkinsonian syndrome in rats induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and oxotremorine Biulleten' Eksperimental'noi Biologii i Meditsiny 108(8): 206-209
Chen, S. 1990: Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse Zhonghua Yi Xue Za Zhi 70(5): 252-254; 18
Harik, S.I.; Schmidley, J.W.; Iacofano, L.A.; Blue, P.; Arora, P.K.; Sayre, L.M. 1987: On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat Journal of Pharmacology and Experimental Therapeutics 241(2): 669-676
Keshavarzian, A.; Haydek, J.M.; Zepeda, D.O.; Stinneford, J.G.; Fields, J.Z. 1990: Gastroduodenal ulcers in rats induced by 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): requirement for gastric acid secretion and the role of prostaglandins Research Communications in Chemical Pathology and Pharmacology 70(1): 21-48
Riachi, N.J.; LaManna, J.C.; Harik, S.I. 1989: Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain Journal of Pharmacology and Experimental Therapeutics 249(3): 744-748
Jenner, P.; Marsden, C.D. 1986: The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease Journal of Neural Transmission. Supplementum 20: 11-39
Di Monte, D.A.; Wu, E.Y.; Delanney, L.E.; Irwin, I.; Langston, J.W. 1992: Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes Journal of Pharmacology and Experimental Therapeutics 261(1): 44-49
Shahi, G.S.; Moochhala, S.M.; Das, N.P.; Sunamoto, J.; Tajima, K. 1990: The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces changes in the heme spin state of microsomal cytochrome P-450 Biochemistry International 22(5): 895-901
Renkawek, K. 1987: Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/MPTP/on mouse substantia nigra in vitro. Fluorescence and electron microscopic examination Progress in Clinical and Biological Research 253: 255-263
Harik, S.I.; Riachi, N.J.; Hritz, M.A.; Berridge, M.S.; Sayre, L.M. 1993: Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies Journal of Pharmacology and Experimental Therapeutics 266(2): 790-795
Boissier, J.R.; Simon, P.; Zaczinska, M.; Fichelle, J. 1972: Experimental psychopharmacologic study of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine Therapie 27(2): 325-338
Zhang, S.R.; Xu, R.M.; Jin, B.Y.; Wu, Y.L.; Han, C. 1996: Protection of dl-(15R)-15 methyl-PGE2 methyl ester (PG6E) on experimental ulcers in rats Yao Xue Xue Bao 31(10): 746-750
Sarles, H.; Camatte, R. 1970: Therapeutic action of phenyl-dimethoxy-2'-4' phenyl-methyl-carbinol and of a vesicular endothelium extract in dyspeptic disorders, fat intolerance and steatorrhea Marseille Medical 107(6): 513-516
Tatematsu, M.; Katsuyama, T.; Fukushima, S.; Takahashi, M.; Shirai, T.; Ito, N.; Nasu, T. 1980: Mucin histochemistry by paradoxical concanavalin a staining in experimental gastric cancers induced in Wistar rats by N-methyl-N-nitro-N-nitrosoguanidine or 4-nitroquinoline 1-oxide Journal of the National Cancer Institute 64(4): 835-843
Kindt, M.V.; Heikkila, R.E.; Nicklas, W.J. 1987: Mitochondrial and metabolic toxicity of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine Journal of Pharmacology and Experimental Therapeutics 242(3): 858-863
Sladowska, H.; Zawisza, T. 1986: Synthesis and properties of amides of 1-benzyl-3-methyl- and 1-butyl-3-phenyl-7-methyl-4-oxo-2-thioxo (2,4-dioxo)-1,2,3,4-tetrahydropyrido-[2,3-d]pyrimidine-6-carboxy lic acids Il Farmaco; Edizione Scientifica 41(12): 954-963
Wagner, G.; Dietzsch, B.; Krake, U. 1975: Gluco- and xylopyranosides of 3-phenyl-4-methyl-(1,2,4)-triazoline- 5-thiones and 3-phenyl-(1,3,4)-thiadiazoline-5-thiones Die Pharmazie 30(11): 694-698
Dyer, D.C.; Benington, F.; Morin, R.D. 1975: Antagonism of d-lysergic acid diethylamide and mescaline by 1-methyl-1, 2, 5, 6-tetrahydropyridine-N, N-diethyl-carboxamide (THPC) Archives Internationales de Pharmacodynamie et de Therapie 217(2): 197-200
Hagen, V.; Rumler, A.; Klauschenz, E.; Hagen, A.; Heer, S.; Faust, G.; Mitzner, R. 1990: Potential cardiotonics. 7. Synthesis and cardiovascular effects of 5-(4-pyridinyl)-, 6-methyl-4-(4-pyridinyl) and 6-methyl-5-phenyl-substituted 3-cyano-2-aminoalkylamino-pyridines Die Pharmazie 45(4): 240-241
Biniecki, S.; Horoszkiewicz, Z. 1974: Synthesis of indolyl-3-acetic acid (1-phenyl-2-3-dimethyl-5-oxo-4-pyrazolyl) amide of 3-indolylacetic acid and N-methyl-(1-phenyl-2,3-3-indolylacetic acid Acta Poloniae Pharmaceutica 31(2): 151-155